Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

overall survival was 9.7 months and that 12 of the 41 evaluable patients are currently alive. No incidences of rash were noted and results were reported to be comparable to intense chemotherapy and radiotherapy. Quality of life was reported as excellent when compared with intensive chemotherapy. Current and planned studies will expand the use of nimotuzumab from the pediatric population to adults with high grade brain tumors.

"Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth

factor receptor (EGFR) monoclonal antibody (MAb), in patients with

unresectable squamous cell carcinoma of the head and neck (SCCHN): A

SENDO Foundation study" (Abstract number 6070): Ten patients with advanced SCCHN, unsuitable for chemo-radiotherapy, were enrolled in a single center phase Ib clinical trial, where they received eight weekly infusions of nimotuzumab at two dose levels: 200mg and 400mg. Paired biopsies were taken from skin and primary tumors, before and 1 week after first infusion.

Nimotuzumab was well tolerated and there was no evidence of skin rash in any of the treated patients. Objective Response was achieved in 80% of patients (2 Complete Responses, 6 Partial Responses) and median survival time was 7.2 months. Results also demonstrated that after a short period of exposure, nimotuzumab as a single agent inhibited EGFR phosphorylation and this was accompanied by a trend towards molecular downstream effects consistent with the expected biological effects of EGFR targeting. The absence of inflammatory skin reaction might be linked to the lack of skin toxicity by the drug.

In addition, YM BioSciences presented data, described in a separate press release issued today by the Company, based on the following poster:
"Preliminary results of an escalating dose phase I clinical trial of the

anti-EGFR monoclonal antibody nimotuzumab in combination with external

radiotherapy in patients diagnosed
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... ... to cap the well that is leaking vast quantities of oil into ... cleaning up the oil that is slowly creeping ashore and affecting sensitive ... end, however, significant obstacles prevent current methods of bioremediation from being effective. ...
... June 3 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... autoimmune disorders, today announced Colin Hislop , M.D. has been promoted ... James E. Pennington , M.D., who will continue to serve as ... , ...
... June 3 Alexandria Real Estate Equities, Inc. (NYSE: ... Science Industry®, today announced that the Cambridge Planning Board has ... known as the Binney Street Project.  This development, with its ... East Cambridge, is positioned to be the epicenter of Cambridge,s ...
Cached Biology Technology:Evolugate Launches Bioremediation Project To Mitigate The Gulf Oil Spill 2Evolugate Launches Bioremediation Project To Mitigate The Gulf Oil Spill 3Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 2Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 3Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 4Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community 2Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community 3
(Date:8/20/2014)... into a chili pepper causes a burning spiciness that ... exploring the chili pepper,s effect are using their findings ... of pain, which can be caused by inflammation or ... which is being tested in clinical trials, in ACS, ... and colleagues explain that decades ago, scientists had pegged ...
(Date:8/20/2014)... who are poor experience higher cortisol levels in pregnancy ... the stress hormone, putting them at greater risk ... new research from the University of Colorado Denver. , ... Journal of Human Biology , is the first to ... the socioeconomic status of their mothers during pregnancy. , ...
(Date:8/20/2014)... State University researchers have developed methods for electronically manipulating ... electrical signals moths use to control those muscles. The ... moths, or "biobots," for use in emergency response. , ... we can control the movement of moths for use ... Dr. Alper Bozkurt, an assistant professor of electrical and ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Research paves way for development of cyborg moth 'biobots' 2
... Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) ... transplanted into patients with diabetes who are suffering from ... a complication of diabetes. The team of researchers in ... results in a recent issue of Cell Transplantation ...
... Jellyfish are increasing in the majority of the world,s ... jellyfish abundance by University of British Columbia researchers. ... the journal Hydrobiologia , UBC scientists examined data ... world,s 66 Large Marine Ecosystems. They found increasing jellyfish ...
... to punish others who lie, cheat, steal or violate other ... to benefit personally, is a distinctly human behavior. There is ... this "I punish you because you harmed him" fashion. Although ... institutionalized in human legal systems and economists have identified it ...
Cached Biology News:Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2Jellyfish on the rise: UBC study 2Crime and punishment: The neurobiological roots of modern justice 2Crime and punishment: The neurobiological roots of modern justice 3Crime and punishment: The neurobiological roots of modern justice 4Crime and punishment: The neurobiological roots of modern justice 5
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... Pre-tested for optimal colony ... the growth of anchorage-dependent ... methylcellulose colony-forming assays of ... cells. Not suitable for ...
... simultaneous dual parameter assay for mitochondrial ... activity. Active caspases are detected by ... which are cell-permeable, non-cytotoxic and bind ... the cells. At the same time ...
Biology Products: